-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades 10x Genomics to Equal-Weight, Raises Price Target to $20

Benzinga·12/02/2025 14:23:45
Listen to the news
Morgan Stanley analyst Tejas Savant downgrades 10x Genomics (NASDAQ:TXG) from Overweight to Equal-Weight and raises the price target from $17 to $20.